Literature DB >> 12170390

Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis.

David H Mattson1.   

Abstract

With the development of multiple options for immunotherapy in multiple sclerosis, the clinician is faced with the challenge of keeping pace with the literature, acquiring familiarity with the various treatment options and opinions, and then offering the patients the most current and appropriate management. Given the inherent nature of a multifocal and unpredictable disease such as multiple sclerosis, along with the availability of multiple treatment options, it behooves the clinician to develop an evidence-based rationale for how to best manage patients. This article reflects the common questions that arise from referring neurologists regarding my personal approach to the management of patients with multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170390     DOI: 10.1055/s-2002-33045

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  2 in total

1.  Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database.

Authors:  Mieko Ogino; Izumi Kawachi; Kazuyoshi Otake; Hiroyuki Ohta; Yujiro Otsuka; Kosuke Iwasaki; Shinzo Hiroi
Journal:  Clin Exp Neuroimmunol       Date:  2016-03-23

2.  A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT's) in multiple sclerosis (MS).

Authors:  Archibald de Ceuninck van Capelle; Hanneke van der Meide; Frans J H Vosman; Leo H Visser
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.